

Long-term Outcomes and Survivorship Following Primary Hip Arthroscopy: A Systematic Review

1Medical College of Wisconsin, Milwaukee, WI, 52336 2Keck School of Medicine of the University of Southern California, Los Angeles, CA, 90033 3Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT, 06519 4University of Connecticut School of Medicine, Farmington, CT, 06032 5Advanced Orthopaedics & Sports Medicine, San Francisco, CA, 94108

INTRODUCTION

At two-year follow-up, multiple studies have reported significant improvement in postoperative outcomes and high rates of non-conversion to THA as high as 98.9%. This trend is consistent at minimum five-year follow-up with multiple studies reporting high rates of patient satisfaction and rates of non-conversion to THA as high as 93%. Recent studies have demonstrated that hip arthroscopy is durable at minimum 10-year follow-up. However, the previous review does not account for the recent spike in literature on long-term outcomes after hip arthroscopy which necessitates an updated review

AIM

- 1) to evaluate minimum 10-year PROs (patient-reported) outcomes) and survivorship after primary hip arthroscopy
- 2) to identify predictors of failure for secondary arthroscopy and conversion to total hip arthroplasty (THA).

METHOD

A systematic review of the literature was conducted with the following keywords: "hip arthroscopy," "long-term," "outcomes," "ten-year," "survivorship," "10-year," "15-year," "fifteen-year," 20-year," "twenty-year," and "femoroacetabular impingement" in PubMed and Cochrane in March 2022 using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Level I to Level IV were included and reported on minimum 10-year outcomes or greater after primary hip arthroscopy. Long-term studies were defined as minimum 10-year follow-up in accordance with established standards in the literature. Case reports, review articles, technique articles, and opinion articles were excluded.

Study	TE	seTE		1		95%-CI	(fixed)	(random)
Menge et al. 2021	88.00	13.0000			88.00	[62.52; 113.48]	28.1%	28.1%
Beals et al. 2022	83.00	20.0000			83.00	[43.80; 122.20]	11.9%	11.9%
Philippon et al. 2020	82.00	16.0000		<u> </u>	82.00	[50.64; 113.36]	18.6%	18.6%
Zimmerer et al. 2021	89.30	10.7000			89.30	[68.33; 110.27]	41.5%	41.5%
Figure 2A. Fores	t Plot f	for mHH	§ (modifie	d Harris ¹ Hip	Scor	e)		

Study	TE	seTE	1
Menge et al. 2021 Beals et al. 2022 Philippon et al. 2020	92.00 87.00 90.00	10.0000 16.0000 17.0000	92.00 [7
Figure 2B. Forest	Plot f	or HOS-	ADL (Hip Outcome Score – Act

Study	TE	seTE	ĩ		95%-CI	(fixed)	Weight (random)
Menge et al. 2021	92.00	10.0000		92.00	[72.40; 111.60]	57.6%	57.6%
Beals et al. 2022	87.00	16.0000		87.00	[55.64; 118.36]	22.5%	22.5%
Philippon et al. 2020	90.00	17.0000		90.00	[56.68; 123.32]	19.9%	19.9%

Figure 2C. Forest Plot for HOS-SSS (Hip Outcome Sore – Sports Specific Subscale)

M. LEE¹, J. OWENS², D. KIM³, S. GILLINOV³, R. MAHATME⁴, S. FONG⁵, J. SIMINGTON⁴, W. ISLAM³, N. GRIMM⁶, <u>A. JIMENEZ³</u>



Weight Weight 95%-CI (fixed) (random) 72.40; 111.60] 57.6% 57.6% 55.64; 118.36] 22.5% 22.5% 56.68; 123.32] 19.9% 19.9%

tivities of Daily Living)

95%-CI	Weight (fixed)	Weight (random)

CONCLUSIONS

- secondary surgeries.
- survivorship.
- conversion to THA

• At long-term follow-up, patients who underwent primary hip arthroscopy demonstrated favorable outcomes and variable rates of

 Patients undergoing hip arthroscopy within the last 20 years with Tonnis Grade < 1 and labral repair experienced over 90%

Chondral damage and older age were the most cited predictors for



© Poster Template by Genigraphics® 1.800.790.4001 www.genigrai

 Rates of secondary arthroscopy ranged conversion to THA varied from 0%-44.1%. Older age and chondral damage were the most commonly cited predictors for

PROs and 8 studies reported significant improvement after hip arthroscopy at longterm follow-up. The remaining two studies reported favorable outcomes that satisfied clinical benefit thresholds at minimum 10year follow-up. Five studies reported clinical benefit where each patient cohort achieved 80% minimal clinically important difference (MCID) and 75% patient

follow-up ranged from 10 to 20 years.

• Twelve studies met the inclusion criteria. In total, 4 studies were level III, and 8

